

1 **Is there a causal relationship between executive function and liability to mental health**  
2 **and substance use? A Mendelian randomisation approach**

3 Sabrina M. I. Burton<sup>1</sup>, Hannah M. Sallis<sup>1,2,3</sup>, Alexander S. Hatoum<sup>4</sup>, Marcus R. Munafò<sup>1,2,5</sup>,

4 Zoe E. Reed<sup>1,2\*</sup>

5 1 School of Psychological Science, University of Bristol, Bristol, UK

6 2 MRC Integrative Epidemiology Unit at the University of Bristol, Bristol, UK

7 3 Centre for Academic Mental Health, Population Health Sciences, University of Bristol,

8 Bristol, UK

9 4 Department of Psychiatry, Washington University School of Medicine, St Louis, MO, USA

10 5 National Institute for Health Research Bristol Biomedical Research Centre, University

11 Hospitals Bristol NHS Foundation Trust and University of Bristol, Bristol, UK

12 \*Corresponding author

13 **Abstract**

14 **Background:** Executive function consists of several cognitive control processes that are able  
15 to regulate lower level processes. Poorer performance in tasks designed to test executive  
16 function is associated with a range of psychopathologies such as schizophrenia, major  
17 depressive disorder (MDD) and anxiety, as well as with smoking and alcohol consumption.  
18 Despite these well-documented associations, whether they reflect causal relationships, and  
19 if so in what direction, remains unclear. We aimed to establish whether there is a causal  
20 relationship between a latent factor for performance on multiple executive function tasks –  
21 which we refer to as common executive function (cEF) – and liability to schizophrenia, MDD,  
22 anxiety, smoking initiation, alcohol consumption, alcohol dependence and cannabis use  
23 disorder (CUD), and the directionality of any relationship observed.

24 **Methods:** We used a two-sample bidirectional Mendelian randomisation (MR) approach  
25 using genome-wide association study (GWAS) summary data from large cohorts (N=17,310 to  
26 848,460) to examine whether causal relationships exist, and if so in which direction.

27 **Results:** We found evidence of a causal effect of increased cEF on reduced schizophrenia  
28 liability (IVW: OR=0.10; 95% CI 0.05 to 0.19; p-value=3.43x10<sup>-12</sup>), reduced MDD liability (IVW:  
29 OR=0.52; 95% CI 0.38 to 0.72; p-value=5.23x10<sup>-05</sup>), decreased drinks per week (IVW:  $\beta$ =-0.06;  
30 95% CI -0.10 to -0.02; p-value=0.003), and reduced CUD liability (IVW: OR=0.27; 95% CI 0.12  
31 to 0.61; p-value=1.58x10<sup>-03</sup>). We also found evidence of a causal effect of increased  
32 schizophrenia liability on decreased cEF (IVW:  $\beta$ =-0.04; 95% CI -0.04 to -0.03; p-value=3.25x10<sup>-</sup>  
33 <sup>27</sup>), as well as smoking initiation on decreased cEF (IVW:  $\beta$ =-0.06; 95%CI -0.09 to -0.03; p-  
34 value=6.11x10<sup>-05</sup>).

35 **Conclusion:** Our results indicate a potential bidirectional causal relationship between a latent  
36 factor measure of executive function (cEF) and schizophrenia liability, a possible causal effect  
37 of increased cEF on reduced MDD liability, CUD liability, and alcohol consumption, and a  
38 possible causal effect of smoking initiation on decreased cEF. These results suggest that  
39 executive function should be considered as a potential risk factor for some mental health and  
40 substance use outcomes, and may also be impacted by mental health (particularly  
41 schizophrenia). Further studies are required to improve our understanding of the underlying  
42 mechanisms of these effects, but our results suggest that executive function may be a  
43 promising intervention target. These results may therefore inform the prioritisation of  
44 experimental medicine studies (e.g., of executive function interventions), for both mental  
45 health and substance use outcomes, to improve the likelihood of successful translation.

## 46 Introduction

47 The ability to perform nearly all of the activities required for daily living is mediated by  
48 executive function (EF)<sup>1</sup> – the ability to perform self-directed behaviour toward a goal and  
49 to enable self-regulation. The prefrontal cortex is the neural substrate of EF, including  
50 cognitive control functions that regulate lower-level processes such as decision making<sup>1</sup>.  
51 There are different aspects of EF, including inhibitory control, working memory and task  
52 switching.

53 EF is thought to be impaired in individuals with a range of mental health problems<sup>1</sup>, and  
54 there is evidence that it is also associated with substance use<sup>2</sup>. For example, poorer EF has  
55 been observed among individuals with schizophrenia<sup>1,3-5</sup>, major depressive disorder  
56 (MDD)<sup>6,7</sup>, and anxiety<sup>8,9</sup>, as well as in people who smoke both cigarettes<sup>10,11</sup> and  
57 cannabis<sup>12,13</sup> and consume alcohol<sup>10,14</sup>. The direction of association between EF and these  
58 phenotypes is unclear<sup>1</sup>, with some studies suggesting EF deficits prior to these<sup>2</sup> and others  
59 suggesting they occur after<sup>3</sup>. It is unclear whether these associations represent causal  
60 pathways, and if so what the direction of any causal effect might be. EF is potentially  
61 modifiable<sup>15</sup>, and drug repurposing analyses for a common EF factor (cEF) score<sup>16</sup> have  
62 suggested that this cEF may also be modifiable. Therefore, if we can better understand the  
63 relationship between EF and mental health and substance use outcomes, this will help to  
64 inform intervention development.

65 Mendelian randomisation (MR) is a well-established method for causal inference, which relies  
66 on approximations of Mendel's laws of segregation and random assortment<sup>17</sup>. MR is based  
67 on instrumental variable (IV) analysis, with single nucleotide polymorphisms (SNPs) that are  
68 robustly associated with the exposure used as IVs. MR is subject to three core assumptions:

69 i) the genetic instrument is robustly associated with the exposure of interest (relevance), ii)  
70 there is no confounding of the genetic instrument and the outcome (independence), and iii)  
71 the genetic instrument only influences the outcome via the exposure (exclusion restriction).  
72 There are different MR methods that test potential violations of these assumptions and  
73 therefore a consistent effect estimate across different approaches would provide greater  
74 evidence of a truly causal effect, robust to the assumptions of MR. MR minimises the effect  
75 of confounding variables as the genetic variants are randomly assigned at conception<sup>18</sup>. It also  
76 overcomes issues around reverse causation as these genetic variants precede any  
77 outcomes<sup>19</sup>.

78 Summary data from genome-wide association studies (GWAS) can be used as the genetic  
79 instruments in MR. A recent GWAS of cEF score, conducted in the UK Biobank (European  
80 ancestry), identified 90 genome-wide significant hits<sup>16</sup>. The factor score was created from  
81 five different EF tasks – trail making, symbol-digit substitution, digit span, prospective  
82 memory, and pairs memory – using confirmatory factor analysis. Unlike, previous studies  
83 focusing on specific EF tasks, the cEF incorporates multiple facets which may better capture  
84 the cognitive component of psychopathology. In particular, single executive function tasks  
85 are noisy measures of executive functioning, with large method variance components  
86 reflecting lower level cognitive processes (the “task impurity problem”<sup>20</sup>). By combining  
87 multiple tasks, we can create a more “pure” measure of executive functioning. Further, past  
88 work has shown that this common component is correlated with – but separable from – IQ,  
89 and is genetically associated with psychopathology over and above the genetic influence of  
90 other cognitive factors<sup>16</sup>.

91

92 We examined whether there were causal relationships between EF and a range of mental  
93 health and substance use phenotypes, and the direction of any effect – for example, does  
94 poor mental health lead to poorer EF, or vice versa? We did this by applying a two-sample MR  
95 approach, where the SNP-exposure and SNP-outcome estimates are obtained from genome-  
96 wide association studies (GWAS) in independent samples and used to estimate causal effects.  
97 We focused on schizophrenia, MDD, anxiety, smoking initiation, alcohol consumption (drinks  
98 per week), alcohol dependence, and cannabis use disorder (CUD), using a bidirectional  
99 approach to determine the causal direction of these relationships.

100 **Methods**

101 **Data Sources**

102 We used GWAS data from several studies, shown in Table 1. To minimise sample overlap,  
103 we excluded some samples that contributed to the original GWAS in our analyses, as  
104 indicated in Table 1.

105 **Table 1.** GWAS for executive function, mental health and substance use outcomes.

Phenotype	Author	Sample	Final N
Executive function	Hatoum et al, 2020 <sup>16</sup>	UKBB	427,037
Schizophrenia	Schizophrenia Working Group of the PGC, 2020 <sup>21</sup>	PGC	Cases = 69,369 Controls = 236,642
Major depressive disorder	Wray et al, 2018 <sup>22</sup>	PGC, excluding UKBB and 23andMe	Cases = 45,396 Controls = 97,250
Anxiety	Otowa et al, 2016 <sup>23</sup>	ANGST	Cases = 5,712 Controls = 11,598
Smoking initiation	Liu et al, 2019 <sup>24</sup>	GSCAN, excluding UKBB	848,460
Drinks per week	Liu et al, 2019 <sup>24</sup>	GSCAN, excluding UKBB	630,154
Alcohol dependence	Walters et al 2018 <sup>25</sup>	PGC Substance Use Disorders working group	Cases = 8,485 Controls = 20,272
Cannabis use disorder	Johnson et al, 2020 <sup>26</sup>	PGC Substance Use Disorders working group, iPSYCH and deCODE	Cases = 14,080 Controls = 343,736

106 *UKBB= UK Biobank, PGC= Psychiatric Genomics Consortium, ANGST= Anxiety NeuroGenetics Study,*

107 *GSCAN= GWAS and Sequencing Consortium of Alcohol and Nicotine use*

108

109 *Executive function.* We used summary data from the most recent GWAS of cEF<sup>16</sup>, which  
110 identified 90 independent genome-wide significant ( $p < 5 \times 10^{-08}$ ) SNPs associated with a cEF  
111 score, where a higher score reflects increased EF.

112 *Schizophrenia.* We used summary data from the most recent Psychiatric Genomics  
113 Consortium (PGC) GWAS of schizophrenia<sup>21</sup>, which identified 294 independent genome-  
114 wide significant SNPs. Cases mostly included participants diagnosed with schizophrenia  
115 (although diagnoses of other psychotic disorders were also included in some samples).

116 *Major depressive disorder (MDD).* We used summary data from the most recent PGC GWAS  
117 of MDD<sup>22</sup>, which identified 44 independent genome-wide significant SNPs. Cases of MDD  
118 were either diagnosed by a clinical professional, or through structured interviews with  
119 trained interviewers, using the DSM IV, ICD-9 or ICD-10 criteria.

120 *Anxiety.* We used summary data from a GWAS of anxiety<sup>23</sup>, which identified one  
121 independent genome-wide significant SNP. In this meta-analysis, there were up to five  
122 different anxiety disorder phenotypes included in the nine samples from seven independent  
123 cohorts. Lifetime DSM-based anxiety disorder diagnostic assessments were available for all  
124 cohorts except for the Rotterdam study, in which only one-year prevalence was assessed.  
125 Each study assessed DSM-based criteria for the following six-lifetime clinical phenotypes:  
126 generalised anxiety disorder (GAD), panic disorder, agoraphobia, social phobia, specific  
127 phobia and MDD, however, any subject reporting a mood disorder only was removed from  
128 analyses.

129 *Smoking initiation.* We used summary data from the most recent GWAS of smoking  
130 initiation<sup>24</sup>, which identified 378 conditionally independent genome-wide significant SNPs



131 associated with ever being a regular smoker (current or former). Participants were asked  
132 whether they had smoked more than 100 cigarettes in their lifetime and whether they had  
133 ever smoked every day for at least a month or ever smoked regularly. To obtain summary  
134 statistics for the full sample included in the GWAS and Sequencing Consortium of Alcohol  
135 and Nicotine use (GSCAN) GWAS excluding UK Biobank data, we meta-analysed results from  
136 GWAS of 23andMe, Inc. only data and all results excluding UK Biobank and 23andMe. The  
137 meta-analysis was conducted using the genome-wide association meta-analysis (GWAMA)  
138 software<sup>27</sup>.

139 *Drinks per week.* We used summary data from the most recent GWAS of drinks per week<sup>24</sup>,  
140 which identified 99 conditionally independent genome-wide significant SNPs associated  
141 with the average number of drinks a participant reported drinking each week. Participants  
142 were asked about the number of alcoholic beverages they had in the past week and the  
143 average number of drinks per week than they had in the past year. Data were log-  
144 transformed prior to the GWAS. This measure did not account for the type of alcohol  
145 consumed and for any study with ranges, the mid-range value was used. Again, to obtain  
146 summary statistics for the full GSCAN GWAS excluding UK Biobank data, we meta-analysed  
147 results from GWAS of 23andMe only data and all results excluding UK Biobank and  
148 23andMe.


149 *Alcohol Dependence.* We used summary data from the PGC substance use disorders working  
150 group GWAS of alcohol dependence<sup>25</sup>, which identified one conditionally independent  
151 genome-wide significant SNPs in their European GWAS associated with alcohol dependence.  
152 Alcohol dependence cases were those that met criteria for DSM-IV or DSM-III-R alcohol  
153 dependence diagnosis.

154 *Cannabis Use Disorder (CUD)*. We used summary data from the most recent GWAS of CUD<sup>26</sup>  
155 from the PGC substance use disorders working group, iPSYCH and deCODE which identified  
156 2 conditionally independent genome-wide significant SNPs associated with CUD. CUD cases  
157 were those that met criteria for DSM-5, DSM-IV, DSM-III-R or ICD-10 cannabis abuse or  
158 dependence.

## 159 **Statistical analyses**

160 The analysis plan for this study was pre-registered on the Open Science Framework  
161 (<https://osf.io/j3tb5>). We conducted two-sample MR analyses using R (version 4.0.3)<sup>28</sup> and  
162 the package TwoSampleMR (version 0.5.0)<sup>29,30</sup>. In order to assess potential bidirectional  
163 pathways, we conducted two-sample MR analyses with cEF as the exposure for one  
164 direction, and as the outcome in the other direction (see Figure 1), when assessing causal  
165 relationships with liability to schizophrenia, MDD, anxiety, smoking initiation, drinks per  
166 week, alcohol dependence and CUD.

167 **Figure 1.** Bidirectional two-sample Mendelian randomisation between a common executive  
168 function factor score and liability to mental health and substance use outcomes



169

170 *Directed acyclic graph for the potential causal effects being examined with a) executive function as*

171 *the exposure and liability to mental health and substance use phenotypes as the outcomes and b)*

172 *liability to mental health and substance use phenotypes as the exposures and executive function as*

173 *the outcome. MDD=Major depressive disorder, CUD=Cannabis use disorder*

174 We used independent genome-wide significant SNPs for the exposure of interest as

175 instruments in the MR analyses, except when anxiety, alcohol dependence and CUD were

176 the exposures, where we used a p-value threshold of  $1 \times 10^{-05}$  to select SNPs due to the low

177 number of genome-wide significant SNPs. We excluded all SNPs in linkage disequilibrium

178 (LD) using an  $r^2$  of 0.001, a window of 10000 kb and the European 1000 genomes reference

179 panel. Where there were palindromic SNPs, we tried to infer the positive strand based on

180 allele frequencies, but if this was not possible, then these SNPs were also excluded. Where

181 an exposure SNP was not available in the outcome data, we attempted to identify a suitable

182 proxy SNP using the LDproxy tool from LDlink<sup>31</sup>. We pruned the SNPs extracted to  $r^2 \geq 0.8$  and

183 extracted the first SNP that was present in the exposure and outcome data. After exclusions  
184 and identifying any proxy SNPs we searched for the remaining cEF SNPs in the outcome  
185 GWAS (73 for schizophrenia, 85 for MDD, 83 for anxiety, 82 for smoking initiation, 83 for  
186 drinks per week, 73 for alcohol dependence and 73 for CUD) and the remaining mental  
187 health and substance use exposure SNPs in the cEF outcome (175 for schizophrenia, 29 for  
188 MDD, 17 for anxiety, 187 for smoking initiation, 67 for drinks per week, 19 for alcohol  
189 dependence and 37 for CUD). The GWAS summary statistics for the exposure and outcome  
190 in each analysis were harmonised so that the SNP allele-exposure and SNP allele-outcome  
191 associations were in the same direction.

192 We used several different MR methods to assess these putative causal relationships:  
193 inverse-variance weighted (IVW)<sup>32</sup>, MR-Egger<sup>33</sup>, weighted median<sup>34</sup>, simple mode and  
194 weighted mode<sup>35</sup>, and Steiger filtering<sup>36</sup> MR methods. We used the IVW approach as our  
195 main method with the other methods used as sensitivity analyses.

196 The IVW approach constrains the intercept to pass through zero, assuming no horizontal  
197 pleiotropy. We tested for heterogeneity between the individual SNPs included in the genetic  
198 instrument using Cochran's test of heterogeneity. The MR-Egger method tests for overall  
199 directional pleiotropy by not constraining the intercept to pass through zero. If the intercept  
200 is not zero then this is indicative of directional horizontal pleiotropy. We also assessed  
201 heterogeneity between the individual SNPs whilst adjusting for any directional pleiotropy  
202 for the MR-Egger method using Rucker's Q test. We used the weighted median method to  
203 obtain estimates under the assumption that at least 50% of the SNPs satisfy the MR  
204 assumptions and are valid IVs. Finally, we used the mode-based approaches to obtain  
205 estimates for the largest cluster of SNPs, where SNPs not in that cluster could be invalid. The

206 weighted method accounts for the largest weights of SNPs. We also conducted single SNP  
207 and leave-one-out analyses.

208 Where we found evidence of a bidirectional causal relationship, we ran Steiger filtering. This  
209 allows orientation of the direction of effect where the underlying biology of genetic variants  
210 is less clear, by identifying which SNPs explain more variance in the outcome than the  
211 exposure and then repeating the MR analyses excluding those SNPs to rule out reverse  
212 causation<sup>36</sup>.

213 In cases where we found evidence for a causal effect between a given exposure and  
214 outcome, we present plots of these results in the Supplementary Material. These plots  
215 include scatter plots of the SNP-exposure and SNP-outcome associations with the causal  
216 effect estimates from each MR method presented, forest plots for causal effects of each  
217 SNP in the instrument (which can indicate if heterogeneity is present), plots presenting the  
218 leave-one-out results and funnel plots of each SNP included in the instrument, where a  
219 symmetrical plot indicates that the effects of each SNP included are similar to the average  
220 effect and asymmetry may indicate horizontal pleiotropy.

221 We calculated weighted and unweighted regression dilution I-squared statistics for each  
222 analysis<sup>37</sup>, presented in Supplementary Table S1, which give an indication of the amount of  
223 bias in the 'NO Measurement Error' (NOME) assumption in the MR-Egger estimate<sup>34</sup>. If the I-  
224 squared statistic is 0.9 or above this indicates minimal bias in the MR-Egger estimate and  
225 therefore we present the MR-Egger results for these associations. If either the weighted or  
226 unweighted I-squared statistics were between 0.6 and 0.9, this may indicate regression  
227 dilution bias and therefore we ran simulation extrapolation (SIMEX) corrections, to obtain  
228 bias-adjusted point estimates for MR-Egger and we present these results in place of MR-

229 Egger. Anything below 0.6 means that the bias may be too large and therefore we do not  
230 report either the SIMEX correction or the MR-Egger results. We also estimated the mean F-  
231 statistic for each analysis, indicative of instrument strength, where a value under 10 may  
232 indicate a weak instrument<sup>37</sup>.

### 233 **Data availability**

234 The data used in this study are publicly-available GWAS data for cEF (available upon request  
235 by contacting the authors), schizophrenia ([https://www.med.unc.edu/pgc/download-](https://www.med.unc.edu/pgc/download-results/scz/)  
236 [results/scz/](https://www.med.unc.edu/pgc/download-results/scz/)), MDD ([https://www.med.unc.edu/pgc/download-](https://www.med.unc.edu/pgc/download-results/mdd/)  
237 [results/angst/?choice=Other+GWAS+DataAnxiety+Neuro+Genetics+Study+%28ANGST%29](https://www.med.unc.edu/pgc/download-</a><br/>238 <a href=)),  
239 smoking initiation and drinks per week (data with UK Biobank and 23andMe removed can  
240 be found here: <https://conservancy.umn.edu/handle/11299/201564>, and for 23andMe data  
241 access needs to be requested (see below), alcohol dependence  
242 (<https://figshare.com/articles/dataset/sud2018-alc/14672187>) and CUD  
243 (<https://figshare.com/articles/dataset/sud2020-cud/14842692>). The full GWAS summary  
244 statistics for the 23andMe discovery data set will be made available through 23andMe to  
245 qualified researchers under an agreement with 23andMe that protects the privacy of the  
246 23andMe participants. Please visit [https://research.23andme.com/collaborate/#dataset-](https://research.23andme.com/collaborate/#dataset-access/)  
247 [access/](https://research.23andme.com/collaborate/#dataset-access/) for more information and to apply to access the data.

### 248 **Code availability**

249 The analysis code that forms the basis of the results presented here is available from the  
250 University of Bristol's Research Data Repository (<http://data.bris.ac.uk/data/>), DOI : To be  
251 made available upon publication).

## 252 Results

253 Our two-sample MR results for the causal effects of cEF on mental health and substance use  
254 outcomes are presented in Table 2.

255 *Schizophrenia.* We found strong evidence of a causal effect of increased cEF on reduced  
256 odds of schizophrenia (IVW: OR=0.10; 95% CI 0.05 to 0.19; p-value= $3.43 \times 10^{-12}$ ) for all  
257 methods except MR Egger, which we were unable to estimate due to violation of the NOME  
258 assumption (See Supplementary Table S1). These results were in a consistent direction  
259 across the different MR analyses (Supplementary Figure S1). However, we did observe  
260 evidence of heterogeneity for the IVW estimate (Supplementary Figure S2) and some  
261 asymmetry in the funnel plot (Supplementary Figure S3), although our leave one out  
262 analyses did not indicate that a single SNP was driving the association (Supplementary  
263 Figure S4). Steiger filtering indicated that only 41% of SNPs instrumenting cEF explained  
264 more variance in cEF than schizophrenia, and results were attenuated when repeating  
265 analyses with this subset of SNPs. However, these results were in the same direction as the  
266 main results (Supplementary Table 2).

267 *Major depressive disorder.* We found strong evidence of a causal effect of increased cEF on  
268 reduced odds of MDD (IVW: OR=0.52; 95% CI 0.38 to 0.72; p-value= $5.23 \times 10^{-05}$ ). These  
269 results were in a consistent direction across the different MR analyses (Supplementary  
270 Figure S5), and there was evidence of a causal effect for all methods except simple mode  
271 and MR Egger, which again we unable to estimate due to violation of the NOME  
272 assumption. Here we also found evidence of heterogeneity for the IVW estimate  
273 (Supplementary Figure S6), and some asymmetry in the funnel plot (Supplementary Figure  
274 S7); however, leave one out analyses did not indicate that a single SNP was driving the



275 association (Supplementary Figure S8). Steiger filtering indicated that 81% of SNPs  
276 instrumenting cEF explained more variance in cEF than MDD, but again results were similar  
277 to the main results when using this subset of SNPs (Supplementary Table 2).

278 *Anxiety*. We did not find evidence of a causal effect of cEF on anxiety liability (IVW: OR=0.49;  
279 95% CI 0.19 to 1.23; p-value=0.13).

280 *Smoking initiation*. We did not find clear evidence of a causal effect of cEF on smoking  
281 initiation (IVW: OR=0.87; 95% CI 0.74 to 1.02; p-value=0.09) for any of the MR analyses.

282 *Drinks per week*. We found some evidence of a causal effect of increased cEF on decreased  
283 number of alcoholic drinks per week consumed (IVW:  $\beta$ =-0.06; 95% CI -0.10 to -0.02; p-  
284 value=0.003). These results were in a consistent direction across the different MR analyses  
285 (Supplementary Figure S9), although there was only evidence of a causal effect for the IVW  
286 method. We also found evidence of heterogeneity here (Supplementary Figure S10) and  
287 slight asymmetry in the funnel plot (Supplementary Figure S11); however, leave one out  
288 analyses did not indicate that a single SNP was driving the association (Supplementary  
289 Figure S12).

290 *Alcohol dependence*. We did not find clear evidence of a causal effect of cEF on alcohol  
291 dependence liability (IVW: OR=0.50; 95% CI 0.23 to 1.28; p-value=0.08) for any of the MR  
292 analyses.

293 *Cannabis Use Disorder (CUD)*. We found strong evidence of a causal effect of increased cEF  
294 on reduced odds of CUD (IVW: OR=0.27; 95% CI 0.12 to 0.61; p-value= $1.58 \times 10^{-03}$ ) for all  
295 methods except MR Egger, which we were unable to estimate due to violation of the NOME  
296 assumption (See Supplementary Table S1). These results were in a consistent direction

297 across the different MR analyses (Supplementary Figure S13). However, we did observe  
298 evidence of heterogeneity for the IVW estimate (Supplementary Figure S14) and slight  
299 asymmetry in the funnel plot (Supplementary Figure S15), although our leave one out  
300 analyses did not indicate that a single SNP was driving the association (Supplementary  
301 Figure S16).

302 **Table 2.** Two-sample Mendelian randomisation results with executive function (cEF) as the exposure.

303

Outcome	Method	NSNPs	OR or beta (95% CI)	P-value	Heterogeneity test p-value	Directional pleiotropy intercept (95% CI; p-value)
Schizophrenia	IVW	73	0.10 (0.05, 0.19)	3.43x10 <sup>-12</sup>	3.52x10 <sup>-61</sup>	
	MR Egger <sup>a</sup>	-	-	-	-	-
	Weighted median	73	0.15 (0.09, 0.24)	1.12x10 <sup>-15</sup>		
	Simple mode	73	0.11 (0.04, 0.33)	2.04x10 <sup>-04</sup>		
	Weighted mode	73	0.12 (0.05, 0.29)	1.53x10 <sup>-05</sup>		
MDD	IVW	85	0.52 (0.38, 0.72)	5.23x10 <sup>-05</sup>	8.22x10 <sup>-03</sup>	
	MR Egger <sup>a</sup>	-	-	-	-	-
	Weighted median	85	0.45 (0.30, 0.67)	1.12x10 <sup>-04</sup>		
	Simple mode	85	0.36 (0.13, 1.10)	0.06		
	Weighted mode	85	0.33 (0.12, 0.96)	0.05		
Anxiety	IVW	83	0.49 (0.19, 1.23)	0.13	0.09	
	MR Egger <sup>b</sup>	83	0.39 (3.67x10 <sup>-4</sup> , 420.28)	0.79		0.002 (-0.05, 0.06; 0.94)
	Weighted median	83	0.31 (0.09, 1.07)	0.07		
	Simple mode	83	0.09 (0.004, 2.03)	0.14		
	Weighted mode	83	0.16 (0.009, 2.99)	0.23		
Smoking initiation	IVW	82	0.87 (0.74, 1.02)	0.09	2.64 x 10 <sup>-67</sup>	
	MR Egger <sup>a</sup>	-	-	-	-	-
	Weighted median	82	0.88 (0.78,0.99)	0.04		
	Simple mode	82	0.81 (0.51,1.29)	0.39		
	Weighted mode	82	0.81 (0.49, 1.37)	0.44		
Drinks per week	IVW	83	-0.06 (-0.10, -0.02)	0.003	8.81x10 <sup>-26</sup>	
	MR Egger <sup>a</sup>	-	-	-	-	-
	Weighted median	83	-0.05 (-0.08, -0.01)	0.008		
	Simple mode	83	-0.05 (-0.14, 0.04)	0.29		
	Weighted mode	83	-0.04 (-0.12, 0.04)	0.33		

Alcohol dependence	IVW	73	0.50 (0.23, 1.09)	0.08	0.17
	MR Egger <sup>a</sup>	-	-	-	-
	Weighted median	73	0.37 (0.12, 1.14)	0.92	
	Simple mode	73	0.33 (0.02, 5.61)	0.44	
	Weighted mode	73	0.47 (-0.04, 5.36)	0.55	
CUD	IVW	73	0.27 (0.12, 0.61)	1.58x10 <sup>-03</sup>	6.17x10 <sup>-09</sup>
	MR Egger <sup>a</sup>	-	-	-	-
	Weighted median	73	0.14 (0.06, 0.35)	1.84x10 <sup>-05</sup>	
	Simple mode	73	0.05 (0.007, 0.38)	4.56x10 <sup>-03</sup>	
	Weighted mode	73	0.08 (0.01, 0.47)	7.19x10 <sup>-03</sup>	

304

305 <sup>a</sup>NO Measurement Error (NOME) assumption violated for MR-Egger and value below 0.6, therefore no results presented. <sup>b</sup>I-squared value between 0.6 and 0.9 so

306 SIMEX correction is presented instead of MR-Egger. MDD=Major depressive disorder, CUD=Cannabis use disorder, OR=odds ratio, CI=confidence interval,

307 IVW=Inverse-variance weighted, MR=Mendelian randomisation, SNP=Single nucleotide polymorphism.

308 Our two-sample MR results for causal effects of the mental health and substance use  
309 phenotypes on cEF are presented in Table 3.

310 *Schizophrenia*. We found strong evidence of a causal effect of increased odds of  
311 schizophrenia on decreased cEF (IVW:  $\beta=-0.04$ ; 95% CI -0.04 to -0.03; p-value= $3.25 \times 10^{-27}$ ).  
312 These results were in a consistent direction across the different MR analyses  
313 (Supplementary Figure S17). However, we did observe evidence of heterogeneity for the  
314 IVW estimate (Supplementary Figure S18) and some asymmetry in the funnel plot  
315 (Supplementary Figure S19), although there was little evidence of directional pleiotropy  
316 from the SIMEX estimate and our leave one out analyses did not indicate that a single SNP  
317 was driving the association (Supplementary Figure S20). Steiger filtering indicated that all  
318 SNPs instrumenting schizophrenia explained more variance in schizophrenia than cEF;  
319 therefore these analyses were not repeated (Supplementary Table 2).

320 *MDD*. We did not find evidence of a causal effect of MDD liability on cEF (IVW:  $\beta=-0.02$ ; 95%  
321 CI -0.05 to 0.01; p-value=0.31) using IVW. However, evidence was stronger using other  
322 sensitivity methods and the direction of effect was consistent across all approaches i.e., for  
323 increased odds of MDD on decreased cEF. Steiger filtering indicated that all SNPs  
324 instrumenting schizophrenia explained more variance in MDD than cEF; therefore these  
325 analyses were not repeated (Supplementary Table 2).

326 *Anxiety*. We did not find evidence of a causal effect of anxiety liability on cEF (IVW:  
327  $\beta=8.69 \times 10^{-04}$ ; 95% CI -0.003 to 0.005; p-value=0.68) for any of the MR analyses.

328 *Smoking initiation*. We found strong evidence of a causal effect of smoking initiation on  
329 decreased cEF (IVW:  $\beta=-0.06$ ; 95% CI -0.09 to -0.03; p-value= $6.11 \times 10^{-05}$ ) and there was

330 evidence of this causal effect using the weighted median method but not the other MR  
331 methods, although the direction of effect was consistent (Supplementary Figure S21). We  
332 did find evidence of heterogeneity for the IVW estimate (Supplementary Figure S22) and  
333 slight asymmetry in the funnel plot (Supplementary Figure S23); however, our leave one out  
334 analyses did not indicate that a single SNP was driving the association (Supplementary  
335 Figure S24).

336 *Drinks per week.* We did not find clear evidence of a causal effect of cEF on number of  
337 alcoholic drinks per week consumed (IVW:  $\beta=-0.007$ ; 95% CI -0.17 to 0.16; p-value=0.93).

338 *Alcohol dependence.* We did not find clear evidence of a causal effect of alcohol dependence  
339 liability on cEF (IVW:  $\beta=-3.31 \times 10^{-03}$ ; 95% CI  $-8.21 \times 10^{-03}$  to  $1.65 \times 10^{-03}$ ; p-value=0.09) for any of  
340 the MR analyses.

341 *Cannabis Use Disorder (CUD).* We did not find clear evidence of a causal effect of CUD  
342 liability on cEF (IVW:  $\beta=-6.42 \times 10^{-03}$ ; 95% CI -0.01 to  $9.56 \times 10^{-04}$ ; p-value=0.09) for any of the  
343 MR analyses.

344 **Table 3.** Two-sample Mendelian randomisation results with executive function (cEF) as the outcome.

345

Exposure	Method	NSNPs	Beta (95% CI)	P-value	Heterogeneity test p-value	Directional pleiotropy intercept (95% CI; p-value)
Schizophrenia	IVW	175	-0.04 (-0.04, -0.03)	3.25x10 <sup>-27</sup>	3.04x10 <sup>-72</sup>	
	MR Egger <sup>b</sup>	175	-0.05 (-0.07, -0.03)	5.77x10 <sup>-05</sup>		9.0x10 <sup>-04</sup> (-6.13x10 <sup>-04</sup> , 0.002; 0.24)
	Weighted median	175	-0.03 (-0.03, -0.02)	8.08x10 <sup>-21</sup>		
	Simple mode	175	-0.04 (-0.06, -0.01)	2.14x10 <sup>-03</sup>		
	Weighted mode	175	-0.04 (-0.06, -0.02)	7.93x10 <sup>-04</sup>		
MDD	IVW	29	-0.02 (-0.05, 0.01)	0.31	3.45x10 <sup>-19</sup>	
	MR Egger <sup>a</sup>	-	-	-	-	-
	Weighted median	29	-0.03 (-0.05, -0.01)	0.01		
	Simple mode	29	-0.04 (-0.08, -0.006)	0.03		
	Weighted mode	29	-0.03 (-0.06, -0.002)	0.04		
Anxiety	IVW	17	8.69x10 <sup>-04</sup> (-0.003, 0.005)	0.68	0.17	
	MR Egger <sup>a</sup>	-	-	-	-	-
	Weighted median	17	7.19x10 <sup>-04</sup> (-0.004, 0.006)	0.78		
	Simple mode	17	0.004 (-0.007, 0.01)	0.49		
	Weighted mode	17	0.002 (-0.007, 0.01)	0.67		
Smoking Initiation	IVW	187	-0.06 (-0.09, -0.03)	6.11x10 <sup>-05</sup>	4.23x10 <sup>-88</sup>	
	MR Egger <sup>a</sup>	-	-	-	-	-
	Weighted median	187	-0.04 (-0.07, -0.01)	2.61x10 <sup>-03</sup>		
	Simple mode	187	-0.01(-0.11, 0.08)	0.80		
	Weighted mode	187	-0.01(-0.12, 0.09)	0.82		

Drinks per Week	IVW	67	-0.007 (-0.17, 0.16)	0.93	1.09x10 <sup>-51</sup>
	MR Egger <sup>a</sup>	-	-	-	-
	Weighted median	67	-0.05 (-0.16, 0.07)	0.45	
	Simple mode	67	-0.10 (-0.31, 0.11)	0.34	
	Weighted mode	67	-0.05 (-0.15, 0.06)	0.41	
Alcohol dependence	IVW	19	-3.31x10 <sup>-03</sup> (-8.21x10 <sup>-03</sup> , 1.65x10 <sup>-03</sup> )	0.19	0.08
	MR Egger <sup>b</sup>	19	-3.74x10 <sup>-03</sup> (-0.01, 3.66x10 <sup>-03</sup> )	0.33	1.93x10 <sup>-05</sup> (-1.99x10 <sup>-03</sup> , 2.03x10 <sup>-03</sup> ; 0.99)
	Weighted median	19	-3.67x10 <sup>-03</sup> (-9.78x10 <sup>-03</sup> , 2.44x10 <sup>-03</sup> )	0.24	
	Simple mode	19	-3.69x10 <sup>-03</sup> (-0.01, 7.25x10 <sup>-03</sup> )	0.52	
	Weighted mode	19	-4.28x10 <sup>-03</sup> (-0.01, 3.58x10 <sup>-03</sup> )	0.30	
CUD	IVW	37	-6.42x10 <sup>-03</sup> (-0.01, -9.56x10 <sup>-04</sup> )	0.09	1.71x10 <sup>-08</sup>
	MR Egger <sup>a</sup>	-	-	-	-
	Weighted median	37	-5.16x10 <sup>-03</sup> (-0.01, 1.98x10 <sup>-03</sup> )	0.16	
	Simple mode	37	-4.65x10 <sup>-03</sup> (-0.02, 9.96x10 <sup>-03</sup> )	0.54	
	Weighted mode	37	-3.65x10 <sup>-03</sup> (-0.02, 0.01)	0.61	

346 <sup>a</sup>NO Measurement Error (NOME) assumption violated for MR-Egger and value below 0.6, therefore no results presented. <sup>b</sup>I-squared value between 0.6 and 0.9 so  
347 SIMEX correction is presented instead of MR-Egger. MDD=Major depressive disorder, CUD=Cannabis use disorder, OR=odds ratio, CI=confidence interval,  
348 IVW=Inverse-variance weighted, MR=Mendelian randomisation, SNP=Single nucleotide polymorphism.



## 349 Discussion

350 We examined whether there was evidence of causal effects of cEF on schizophrenia, MDD,  
351 anxiety, smoking initiation, drinks per week, alcohol dependence and CUD. We also  
352 examined the reverse direction (i.e., causal effects of mental health and substance use on  
353 cEF). Evidence of a causal effect in both directions may be indicative of a bidirectional  
354 relationship or some other underlying common risk factor.

355 Our main findings were evidence of a causal relationship between increased cEF and  
356 reduced schizophrenia liability in both directions. Steiger filtering supported the finding of  
357 bidirectional effects, despite some attenuation of results for cEF on schizophrenia. This  
358 causal effect supports previous observational studies, which have found that people with  
359 schizophrenia have poorer EF<sup>1,3-5</sup>; however, our MR analyses provide evidence that these  
360 associations may reflect causal pathways. The fact that we find causal effects between  
361 schizophrenia liability and cEF in both directions may point to this association being  
362 bidirectional or due to an underlying common risk factor.

363 The observed causal effect of increased cEF on reduced MDD liability is also interesting, as  
364 previous studies have provided mixed evidence for the directionality of this relationship<sup>6,7</sup>.  
365 We did not find strong evidence of a causal effect of MDD on cEF using the IVW approach;  
366 however, evidence was stronger when using other MR methods, and the direction of effect  
367 we observed was negative and consistent across these. It may also be possible that there is  
368 lower power in the MDD instrument than the cEF instrument, due to the lower number of  
369 SNPs, which may also be why we do not observe a consistent effect of MDD on cEF.  
370 Therefore, we cannot rule out the possibility of a bidirectional relationship and Steiger  
371 filtering suggested that the effects could be bidirectional as well. We cannot draw any

372 strong conclusions from our results regarding anxiety and cEF. Whilst we do not find  
373 evidence of a causal relationship, this does not mean that there is definitely no effect, but  
374 rather that our study may have lacked the power to detect a causal effect here, particularly  
375 given that we find some evidence of a possible causal effect of MDD on cEF in our sensitivity  
376 analyses and previous studies have reported high genetic correlations between MDD and  
377 anxiety<sup>38</sup>. Thus the association found in previous studies needs further investigation still<sup>8,9</sup>.

378 Finally, we also found some evidence of a causal effect of smoking initiation on decreased  
379 cEF and increased cEF on decreased drinks per week and reduced CUD liability, all in a  
380 consistent direction with previous observational studies<sup>10-14</sup>. However, evidence for the  
381 smoking and drinks per week findings was weak, so further studies examining this would be  
382 useful.

383 Our results are in contrast to a previous study which used latent causal variable (LCV)  
384 analyses and did not find evidence of any causal effects of cEF on schizophrenia, MDD,  
385 anxiety, alcohol use disorder or other traits examined<sup>16</sup>. LCV analysis relies on the  
386 assumption that there is a latent variable that mediates the genetic correlation between  
387 two traits and uses whole genome summary statistics to estimate genetic causality. One  
388 trait is partially genetically causal for the other if it is strongly genetically correlated with the  
389 LCV. However, LCV aims to capture the overall direction of causality and therefore may be  
390 less appropriate for relationships where a bidirectional effect may be present, as we  
391 observe in our study. Whereas MR does allow for for bidirectional relationships<sup>39</sup>. Although,  
392 LCV has better control for pleiotropy<sup>16</sup>, meaning the difference between our results and  
393 those in the previous LCV analysis may reflect the presence of pleiotropy, which we were  
394 unable to directly test for in several of our analyses. We were able to test this for our MR of

395 schizophrenia on cEF and found no evidence of pleiotropy. However, this should be  
396 considered when interpreting our other results.

### 397 *Limitations*

398 There are a number of limitations to our study that should be considered when interpreting  
399 these results. First, there could be low statistical power to detect causal effects for some of  
400 the analyses. In particular, where anxiety, alcohol dependence and CUD are the exposures  
401 there were a low number of genome-wide significant SNPs. To overcome this issue we  
402 lowered the p-value threshold for our MR analyses to  $1 \times 10^{-5}$ , but this means that any  
403 interpretation of these results should be approached with caution and revisiting this causal  
404 relationship when larger GWAS are available would be valuable. Second, in the majority of  
405 our analyses (i.e., in both directions for schizophrenia, MDD, smoking initiation, drinks per  
406 week and CUD) evidence of heterogeneity was observed in the IVW estimates, which could  
407 suggest that horizontal pleiotropy is present (e.g., that independent pathways are  
408 responsible for the influence of SNPs on the exposure and outcome). Therefore, caution  
409 should be used when interpreting these results. However, we did test for violations of other  
410 MR assumptions using additional MR sensitivity analyses and the direction of the results  
411 were consistent with the direction of the main results. Despite this, in a number of our  
412 analyses we could not test for directional pleiotropy due to the I-squared estimate being too  
413 low.

414 Finally, MR is also subject to some general limitations<sup>40</sup>. For example, the ‘Winner’s curse’  
415 can occur when the SNPs used are based on the discovery GWAS only (as opposed to  
416 combined discovery and replication results), meaning that SNP-trait effects may be  
417 overestimated. This can mean that the MR estimate is biased towards the null. Thus, the

418 focus of our results is on the direction of effect as opposed to the size of any causal effects,  
419 although the latter may still be somewhat informative.

#### 420 *Conclusion*

421 Our findings suggest a bidirectional causal relationship between cEF and schizophrenia  
422 liability, where increased schizophrenia liability is associated with decreased cEF and vice  
423 versa, as well as causal effects of increased cEF on reduced MDD liability and CUD liability  
424 and decreased drinks per week, and a causal effect of smoking initiation on decreased cEF.  
425 These results require further study to better understand the mechanisms behind these  
426 causal effects. Future research would benefit from better powered GWAS for anxiety where  
427 a lack of power may explain why we did not detect any causal effects. Our results may  
428 inform prioritisation of experimental medicine studies (e.g., of interventions targeting EF) to  
429 improve the likelihood of successful translation and suggest that these interventions may be  
430 useful prior to the onset of schizophrenia and MDD in particular.

431 **Acknowledgements:** We thank all the contributors to the consortia we have used GWAS  
432 results from in our analyses. We would like the thank the research participants and  
433 employees of 23andMe for making this work possible.

434 **Funding:** This work was supported by the UK Medical Research Council Integrative  
435 Epidemiology Unit at the University of Bristol (Grant ref: MC\_UU\_00011/7) and the NIHR  
436 Biomedical Research Centre at University Hospitals Bristol NHS Foundation Trust and the  
437 University of Bristol. HMS is supported by the European Research Council (Grant ref: 758813  
438 MHINT). The views expressed in this publication are those of the author(s) and not  
439 necessarily those of the NHS, the National Institute for Health Research or the Department  
440 of Health and Social Care. ASH acknowledges funding from that National Institute on Drug  
441 Abuse (Grant ref: T32DA007261).

442 **Competing interests:** None

443 **Author contributions:** Conceptualization: MRM, ZER; Methodology: SMIB, ZER; Formal  
444 Analysis: SMIB, ZER; Resources: MRM; Data Curation: ZER; Writing—Original Draft: SMIB,  
445 ZER; Writing—Review and Editing: SMIB, HMS, ASH, MRM, ZER; Supervision: MRM, ZER;  
446 Project Administration: MRM, ZER; Funding Acquisition: MRM.

## 447 References

- 448 1. Snyder, H. R., Miyake, A. & Hankin, B. L. Advancing understanding of executive  
449 function impairments and psychopathology: Bridging the gap between clinical and  
450 cognitive approaches. *Front. Psychol.* **6**, 328 (2015).
- 451 2. Kim-Spoon, J. *et al.* Executive functioning and substance use in adolescence:  
452 Neurobiological and behavioral perspectives. *Neuropsychologia* **100**, 79–92 (2017).
- 453 3. Thai, M. L., Andreassen, A. K. & Bliksted, V. A meta-analysis of executive dysfunction  
454 in patients with schizophrenia: Different degree of impairment in the ecological  
455 subdomains of the Behavioural Assessment of the Dysexecutive Syndrome. *Psychiatry*  
456 *Research* vol. 272 230–236 (2019).
- 457 4. Fioravanti, M., Bianchi, V. & Cinti, M. E. Cognitive deficits in schizophrenia: An  
458 updated metanalysis of the scientific evidence. *BMC Psychiatry* **12**, 64 (2012).
- 459 5. Thuaire, F. *et al.* Executive functions in schizophrenia aging: Differential effects of age  
460 within specific executive functions. *Cortex* **125**, 109–121 (2020).
- 461 6. Rock, P. L., Roiser, J. P., Riedel, W. J. & Blackwell, A. D. Cognitive impairment in  
462 depression: a systematic review and meta-analysis. *Psychol. Med.* **44**, 2029–40  
463 (2014).
- 464 7. Schwert, C., Stohrer, M., Aschenbrenner, S., Weisbrod, M. & Schröder, A.  
465 Neurocognitive profile of outpatients with unipolar depressive disorders. *J. Clin. Exp.*  
466 *Neuropsychol.* **41**, 913–924 (2019).
- 467 8. Gulpers, B., Lugtenburg, A., Zuidersma, M., Verhey, F. R. J. & Voshaar, R. C. O. Anxiety

- 468 disorders and figural fluency: A measure of executive function. *J. Affect. Disord.* **234**,  
469 38–44 (2018).
- 470 9. Murphy, Y. E. *et al.* An Investigation of Executive Functioning in Pediatric Anxiety.  
471 *Behav. Modif.* **42**, 885–913 (2018).
- 472 10. Glass, J. M. *et al.* Effects of alcoholism severity and smoking on executive  
473 neurocognitive function. *Addiction* **104**, 38–48 (2009).
- 474 11. Heffernan, T. M., Carling, A., O’Neill, T. S. & Hamilton, C. Smoking impedes executive  
475 function and related prospective memory. *Ir. J. Psychol. Med.* **31**, 159–165 (2014).
- 476 12. Lundqvist, T. Cognitive consequences of cannabis use: Comparison with abuse of  
477 stimulants and heroin with regard to attention, memory and executive functions.  
478 *Pharmacol. Biochem. Behav.* **81**, 319–330 (2005).
- 479 13. Lorenzetti, V., Hoch, E. & Hall, W. Adolescent cannabis use, cognition, brain health  
480 and educational outcomes: A review of the evidence. *Eur. Neuropsychopharmacol.*  
481 **36**, 169–180 (2020).
- 482 14. Martins, J. S., Bartholow, B. D., Cooper, M. L., Von Gunten, C. D. & Wood, P. K.  
483 Associations between executive functioning, affect-regulation drinking motives, and  
484 alcohol use and problems. *Psychol. Addict. Behav.* **32**, 16–28 (2018).
- 485 15. Diamond, A. & Ling, D. S. Conclusions about interventions, programs, and approaches  
486 for improving executive functions that appear justified and those that, despite much  
487 hype, do not. *Dev. Cogn. Neurosci.* **18**, 34–48 (2016).
- 488 16. Hatoum, A. S. *et al.* Genome-Wide Association Study of Over 427,000 Individuals

- 489 Establishes Executive Functioning as a Neurocognitive Basis of Psychiatric Disorders  
490 Influenced by GABAergic Processes. *bioRxiv* 674515 (2020) doi:10.1101/674515.
- 491 17. Davey Smith, G. & Ebrahim, S. ‘Mendelian randomization’: Can genetic epidemiology  
492 contribute to understanding environmental determinants of disease? *International*  
493 *Journal of Epidemiology* vol. 32 1–22 (2003).
- 494 18. Gupta, V., Walia, G. K. & Sachdeva, M. P. ‘Mendelian randomization’: an approach for  
495 exploring causal relations in epidemiology. *Public Health* vol. 145 113–119 (2017).
- 496 19. Carnegie, R. *et al.* Mendelian randomisation for nutritional psychiatry. *The Lancet.*  
497 *Psychiatry* **7**, 208–216 (2020).
- 498 20. Miyake, A. *et al.* The Unity and Diversity of Executive Functions and Their  
499 Contributions to Complex ‘Frontal Lobe’ Tasks: A Latent Variable Analysis. *Cogn.*  
500 *Psychol.* **41**, 49–100 (2000).
- 501 21. Schizophrenia Working Group of the Psychiatric Genomics Consortium., Ripke, S.,  
502 Walters, J. T. & O’Donovan, M. C. Mapping genomic loci prioritises genes and  
503 implicates synaptic biology in schizophrenia. *medRxiv* 2020.09.12.20192922 (2020)  
504 doi:10.1101/2020.09.12.20192922.
- 505 22. Wray, N. R. *et al.* Genome-wide association analyses identify 44 risk variants and  
506 refine the genetic architecture of major depression. *Nat. Genet.* **50**, 668–681 (2018).
- 507 23. Otowa, T. *et al.* Meta-analysis of genome-wide association studies of anxiety  
508 disorders. *Mol. Psychiatry* **21**, 1391–1399 (2016).
- 509 24. Liu, M. *et al.* Association studies of up to 1.2 million individuals yield new insights into



- 510 the genetic etiology of tobacco and alcohol use. *Nature Genetics* vol. 51 237–244  
511 (2019).
- 512 25. Walters, R. K. *et al.* Transancestral GWAS of alcohol dependence reveals common  
513 genetic underpinnings with psychiatric disorders. *Nat. Neurosci.* **21**, 1656–1669  
514 (2018).
- 515 26. Johnson, E. C. *et al.* A large-scale genome-wide association study meta-analysis of  
516 cannabis use disorder. *The Lancet Psychiatry* **7**, 1032–1045 (2020).
- 517 27. Mägi, R. & Morris, A. P. GWAMA: Software for genome-wide association meta-  
518 analysis. *BMC Bioinformatics* **11**, 288 (2010).
- 519 28. R Core Team. R: A language and environment for statistical computing. (2016).
- 520 29. Hemani, G., Tilling, K. & Davey Smith, G. Orienting the causal relationship between  
521 imprecisely measured traits using GWAS summary data. *PLOS Genet.* **13**, e1007081  
522 (2017).
- 523 30. Hemani, G. *et al.* The MR-base platform supports systematic causal inference across  
524 the human phenome. *Elife* **7**, 1–29 (2018).
- 525 31. Machiela, M. J. & Chanock, S. J. LDlink: A web-based application for exploring  
526 population-specific haplotype structure and linking correlated alleles of possible  
527 functional variants. *Bioinformatics* **31**, 3555–3557 (2015).
- 528 32. Burgess, S., Butterworth, A. & Thompson, S. G. Mendelian randomization analysis  
529 with multiple genetic variants using summarized data. *Genet. Epidemiol.* **37**, 658–665  
530 (2013).

- 531 33. Bowden, J., Davey Smith, G. & Burgess, S. Mendelian randomization with invalid  
532 instruments: Effect estimation and bias detection through Egger regression. *Int. J.*  
533 *Epidemiol.* **44**, 512–525 (2015).
- 534 34. Bowden, J., Davey Smith, G., Haycock, P. C. & Burgess, S. Consistent Estimation in  
535 Mendelian Randomization with Some Invalid Instruments Using a Weighted Median  
536 Estimator. *Genet. Epidemiol.* **40**, 304–314 (2016).
- 537 35. Hartwig, F. P., Davey Smith, G. & Bowden, J. Robust inference in summary data  
538 Mendelian randomization via the zero modal pleiotropy assumption. *Int. J. Epidemiol.*  
539 (2017) doi:10.1093/ije/dyx102.
- 540 36. Hemani, G., Tilling, K. & Davey Smith, G. Orienting the causal relationship between  
541 imprecisely measured traits using GWAS summary data. *PLoS Genet.* **13**, e1007081  
542 (2017).
- 543 37. Bowden, J. *et al.* Assessing the suitability of summary data for two-sample mendelian  
544 randomization analyses using MR-Egger regression: The role of the I<sup>2</sup> statistic. *Int. J.*  
545 *Epidemiol.* **45**, 1961–1974 (2016).
- 546 38. Hettema, J. M. What is the genetic relationship between anxiety and depression? *Am.*  
547 *J. Med. Genet. Part C Semin. Med. Genet.* **148C**, 140–146 (2008).
- 548 39. Hines, L. A., Treur, J. L., Jones, H. J., Sallis, H. M. & Munafò, M. R. Using genetic  
549 information to inform policy on cannabis. *The Lancet Psychiatry* **7**, 1002–1003 (2020).
- 550 40. Haycock, P. C. *et al.* Best (but oft-forgotten) practices: The design, analysis, and  
551 interpretation of Mendelian randomization studies. *Am. J. Clin. Nutr.* **103**, 965–978

552 (2016).

553